High expression of BCAT1 is a marker for predicting poor prognosis in IDH1 wild-type glioma patients, providing an important target site for glioblastoma patients (Yi et al., 2021; Huang W. et al., 2022). This evidence concerns the gene IDH1 and glioblastoma.